Menu Skip to investor update materials New GSK, with new ambitions for patients and shareholders The following information relates to the formation of New GSK and how the company plans to drive growth and returns for shareholders. It is intended for those with a specific interest in this area. Our CEO Emma Walmsley discusses our strategy for New GSK, the new growth company positioned to create significant value for patients and shareholders from 2022 and for the next decade. View video on YouTube We expect to deliver a step change in performance with major new commitments to sales and profit growth including more than 5% sales CAGR 2021-26, more than 10% adjusted operating profit CAGR 2021-26 expected and an ambition to deliver more than £33 billion sales by 2031. This transformation will be enabled by New GSK’s growth engine, Vaccines and Specialty Medicines, which we expect to grow to around three-quarters of our revenue base by 2026. View video on YouTube At GSK, we have already delivered unprecedented change over the past four years, improving R&D, becoming a leader in Consumer Health, strengthening our leadership and transforming our commercial execution. Now, we are making our most significant corporate change in more than 20 years, setting out a new ambition for creating value for shareholders and impacting the health of over 2.5 billion people over 10 years. View video on YouTube Watch the event Closing comments Q&A New GSK Investor update Strategic transformation, outlook and ambitions Delivering growth: 2021-2026 and beyond Slides Presentation slides PDF - 7.8MB Strategic transformation, outlook and ambitions PDF - 1.6MB Delivering growth: 2022-2026 and beyond PDF - 2.0MB Vaccines: strengthening leadership PDF - 1.8MB Specialty: reshaping HIV treatment and prevention PDF - 1.5MB Specialty: maximising high potential medicines PDF - 1.7MB Sustainable growth, competitive returns PDF - 1.7MB Closing comments PDF - 1.0MB Additional downloads Full presentation transcript PDF - 269.5KB Q&A transcript PDF - 150.3KB Epidemiology data PDF - 3.3MB Clinical trials summary PDF - 3.5MB Speaker biographies PDF - 8.6MB All materials ZIP - 22.5MB Epidemiology data Clinical trials summary Our speakers Emma Walmsley | Chief Executive Officer Dr Hal Barron | Chief Scientific Officer and President, R&D Download speaker biographies PDF - 8.6MB Quarterly results Discover our latest financial performance announcement and search for historical quarterly results materials. Annual report A summary of the progress we made in 2020 against our long-term priorities of Innovation, Performance and Trust, underpinned by a continuing shift in culture. Also access and download the full Annual Report or individual sections. Our pipeline We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers. For media New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline. Read the press release Download media call slides Investor contacts United Kingdom Tel: +44 (0)20 8047 5000 Email: GSK.Investor-Relations@gsk.com United States Toll free: +1 888 825 5249 Tel: +1 215 751 4000 Email: GSK.Investor-Relations@gsk.com Media contacts Global Headquarters (London, UK) Tim Foley VP, Global Corporate Media Relations Madeleine Breckon Director, Global Corporate Media Relations, Pharmaceuticals Simon Moore Director, Global Corporate Media Relations, Vaccines and Global Public Health Tel: +44 (0)20 8047 5502 Email: corporate.media@gsk.com USA (Philadelphia) Kristen Neese VP, Global Product & Pipeline Communications & US Corporate Communications Email: kristen.x.neese@gsk.com Kathleen Quinn Head, US Corporate Communications Email: kathleen.x.quinn@gsk.com Behind the science Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs. Go behind the science RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL